Since its inception in 1987 until 2012, KIGS (Pfizer International Growth Database) has collected data on the effects of growth hormone (GH) treatment in children and adolescents with growth disorders. The KIGS database has more than 83,000 patients from more than 52 countries registered worldwide and a considerable number of them have been followed to final height. Over the years, KIGS has become a major source of documentation of growth disorders and their treatment with recombinant GH. The collected data are used for scientific research which is coordinated by the KIGS Steering Committee and KIGS Investigators and the outcome is presented in peer-reviewed journals. KIGS data have been used to develop mathematical models that predict the growth response to GH treatment in children with growth disorders. Models such as these allow physicians to assess whether an individual child is responding well to treatment, or whether treatment may need to be adjusted to obtain the best response. As of October 2012 the Database was closed for further data collection, however, it remains as a source for scientific analyses.
The KIGS website can be used to obtain general information on GH treatments in children and adolescents. Registered Clinicians have access to more extensive information.
If you have any questions regarding KIGS, please contact Ferah Aydin, KIGS Manager.
KIGS - How it all started
Growth hormone (GH) has been in clinical use for more than 40 years. Treatment with GH was initially based on pituitary-derived human GH, and owing to the relative scarcity of the product, was limited to children with severe growth hormone deficiency (GHD).
KIGS 20 Years Book
Long-term growth hormone treatment in short children with CKD does not accelerate decline of renal function: result from the KIGS registry and ESCAPE trial
Pediatr Nephrol. 2015 Dec; 30(12): 2145-51